Cargando…
Myocardial Protective Effect of Tezosentan, an Endothelin Receptor Antagonist, for Ischemia-Reperfusion Injury in Experimental Heart Failure Models
The myocardial protective effects of endothelin antagonist in ischemic cardiomyopathy (ICMP), doxorubicin-induced cardiomyopathy (DOX) and pressure-overload hypertrophy by transverse aortic constriction (TAC) models have been predicted to be different. The objective of this experiment, therefore, is...
Autores principales: | Ryu, Se Min, Kim, Hark Jei, Cho, Kyu Ran, Jo, Won-Min |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Korean Academy of Medical Sciences
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2752756/ https://www.ncbi.nlm.nih.gov/pubmed/19794971 http://dx.doi.org/10.3346/jkms.2009.24.5.782 |
Ejemplares similares
-
Repurposing of the Drug Tezosentan for Cancer Therapy
por: Ribeiro, Eduarda, et al.
Publicado: (2023) -
Preventive Role of Endothelin Antagonist on Kidney Ischemia: Reperfusion Injury in Male and Female Rats
por: Afyouni, Nazgol Esmalian, et al.
Publicado: (2015) -
Effects of Endothelin-1 and nitric oxide levels on myocardial ischemia-reperfusion injury
por: Ai, Wenwei, et al.
Publicado: (2022) -
Impact of an Interleukin-1 Receptor Antagonist and Erythropoietin on Experimental Myocardial Ischemia/Reperfusion Injury
por: Grothusen, Christina, et al.
Publicado: (2012) -
Endothelin and Endothelin Antagonists in Chronic Kidney Disease
por: Kohan, Donald E., et al.
Publicado: (2014)